Parsifal Capital Management LP Has $105.75 Million Stock Holdings in The Clorox Company (NYSE:CLX)

Parsifal Capital Management LP decreased its stake in The Clorox Company (NYSE:CLX - Free Report) by 6.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 651,154 shares of the company's stock after selling 42,634 shares during the period. Clorox makes up 8.8% of Parsifal Capital Management LP's portfolio, making the stock its 5th biggest position. Parsifal Capital Management LP owned 0.53% of Clorox worth $105,754,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of CLX. Vanguard Group Inc. grew its position in Clorox by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 15,507,152 shares of the company's stock valued at $2,518,517,000 after acquiring an additional 124,428 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Clorox by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock worth $501,925,000 after purchasing an additional 69,969 shares in the last quarter. Stifel Financial Corp boosted its stake in shares of Clorox by 0.4% in the fourth quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock valued at $380,761,000 after purchasing an additional 9,582 shares during the period. Norges Bank acquired a new stake in Clorox during the 4th quarter valued at $259,041,000. Finally, Northern Trust Corp increased its stake in Clorox by 18.2% during the 4th quarter. Northern Trust Corp now owns 1,494,265 shares of the company's stock worth $242,684,000 after buying an additional 230,173 shares during the period. Institutional investors and hedge funds own 78.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Morgan Stanley decreased their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Evercore ISI set a $140.00 price target on Clorox and gave the stock an "underperform" rating in a research note on Tuesday, May 6th. DA Davidson lowered their price objective on Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Royal Bank of Canada restated a "sector perform" rating and set a $150.00 price objective on shares of Clorox in a report on Thursday, January 30th. Finally, JPMorgan Chase & Co. cut their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $151.23.

Insiders Place Their Bets

In other news, Director Pierre R. Breber purchased 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.57% of the stock is owned by corporate insiders.

Clorox Stock Performance

Clorox stock traded up $1.32 during mid-day trading on Friday, reaching $136.31. The company's stock had a trading volume of 3,182,936 shares, compared to its average volume of 1,320,934. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The Clorox Company has a twelve month low of $127.60 and a twelve month high of $171.37. The business has a 50 day moving average price of $141.05 and a 200-day moving average price of $153.35. The firm has a market cap of $16.80 billion, a price-to-earnings ratio of 37.24, a PEG ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The company's quarterly revenue was down 8.0% on a year-over-year basis. During the same period last year, the firm posted $1.71 earnings per share. Sell-side analysts predict that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 9th. Investors of record on Wednesday, April 23rd were paid a dividend of $1.22 per share. The ex-dividend date of this dividend was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a yield of 3.58%. Clorox's payout ratio is currently 87.61%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.